clobazam / Generic mfg. - LARVOL DELTA

SAFETY AND TOLERABILITY OF A CANNABIS-BASED OIL EXTRACT IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION – A PHASE I STUDY (EBMT 2026) - "Objective: to assess the safety of a cannabis-based oil in patients undergoing aHSCT with high-dose melphalan (HDM) for multiple myeloma and plasma cell dyscrasias...Patients with prior severe psychiatric disorders or using clobazam or valproate were considered ineligible... Most patients either complained of nausea or discontinued therapy shortly after HDM. This transplant period is characterized by a high incidence of dysgeusia, chemotherapy-induced nausea and vomiting and oral mucositis, which may have contributed to poor tolerability of the oil-based CBD formulation. Difficulties in maintaining patients on-protocol, together with budgetary constraints, led investigators to terminate the study early."

Clinical • P1 data • Bipolar Disorder • Bone Marrow Transplantation • Chemotherapy-Induced Nausea and Vomiting • CNS Disorders • Depression • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Mental Retardation • Mood Disorders • Mucositis • Multiple Myeloma • Neutropenia • Stomatitis • Transplantation

Severe Refractory NORSE with Bilateral Thalamostriatal Involvement: Anakinra Rescue After Multidrug Failure (ACTRIMS Forum 2026) - "Extensive infectious, autoimmune, and paraneoplastic evaluation was only positive for norovirus on stool PCR.Despite multiple antiseizure medications (levetiracetam, lacosamide, valproate, phenobarbital, clobazam, rufinamide, perampanel, topiramate, ketamine) plus IVIG, high-dose corticosteroids, and tocilizumab, GPDs persisted and the patient remained critically ill. Cytokine-directed therapy, particularly anakinra, may be effective in cryptogenic NORSE unresponsive to conventional antiseizure and first-line immunotherapies. Early recognition and targeted immunomodulation can improve outcomes in severe, refractory cases."

CNS Disorders • Epilepsy • Immunology • Musculoskeletal Pain

Adjunctive cannabidiol in intractable pediatric epilepsy: A retrospective study on tolerability, efficacy, and safety across genetic and nongenetic etiologies. (PubMed, Medicine (Baltimore)) - "At CBD initiation, patients were receiving a median of 5 antiseizure medications, most commonly valproic acid (93.1%), clobazam (82.8%), and levetiracetam (75.9%). CBD was discontinued in 3 patients due to pneumonia, lethargy, or seizure aggravation. CBD therapy demonstrated favorable retention, efficacy, and safety profiles in pediatric-onset intractable epilepsy across a spectrum of etiologies."

Journal • Observational data • Retrospective data • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases • Vascular Neurology • COL4A1 • KIF1A

Drug-induced cataract: a real-world study based on the food and drug administration adverse event reporting system database. (PubMed, Front Med (Lausanne)) - "The highest-risk drugs identified were omidenepag isopropyl, clobazam, and nitisinone, with BCPNN scores of 7.69, 7.36, and 6.02, respectively. The majority of affected individuals were female (67.59%) and elderly (mean age 63.85 ± 14.54 years). This study provides real-world evidence regarding the risk of drug-induced cataract, offering empirical support for preventive strategies and informed clinical decision-making."

Adverse events • Journal • Real-world evidence • Cataract • Ophthalmology

Epilepsy phenotypes of Renu syndrome: Novel insights from a European multicentre retrospective cohort study. (PubMed, Seizure) - "The phenotype of the seizure disorders observed in this cohort was dominated by focal impaired consciousness seizures with observable manifestations and a relatively favourable course of epilepsy."

Journal • Retrospective data • CNS Disorders • Developmental Disorders • Epilepsy • Mental Retardation • Psychiatry

Efficacy of Dravet Syndrome Treatments in a Subset of Individuals with 2q24.3 Deletion: A-5 Patient Case Series. (PubMed, J Child Neurol) - "We found evidence of efficacy for valproic acid, clobazam, and cannabidiol whereas levetiracetam and phenobarbital were not beneficial. Additional studies are necessary to examine the efficacy of fenfluramine and the ketogenic diet."

Journal • CNS Disorders • Epilepsy

Seizure medications and interictal spiking: Implications for cognition and behavior. (PubMed, Epilepsia) - "The use of sodium channel blockers, such as lamotrigine and oxcarbazepine, produces cognitive improvements. Additionally, γ-aminobutyric acidergic agents, including clobazam and diazepam, are effective in treating developmental epileptic encephalopathies. Emerging therapies, including cannabidiol and perampanel, show promising IED and behavioral outcomes...Targeted reduction of IEDs may lead to improved cognitive and behavioral outcomes. This can be achieved by testing and recognizing ASMs in carefully designed prospective trials in animals and humans."

Journal • Review • CNS Disorders • Epilepsy

KCNT1-related epilepsy presenting with severe polyhydramnios (ACMG 2026) - "Outcome and Follow-Up The infant had APGARS of 5 and 9, and a 49-day course in the NICU with management by neurology for refractory seizures requiring multiple antiepileptic drugs, including a combination of levetiracetam, clobazam, and cannabidiol. The exome sequencing report noted this variant is not associated with the phenotype of severe polyhydramnios. Parental testing was recommended given some cases result from an asymptomatic parent with mosaicism, however, the couple declined."

Cardiovascular • CNS Disorders • Developmental Disorders • Epilepsy • Gene Therapies • Mental Retardation • Movement Disorders • Pulmonary Disease

Beta-propeller protein-associated neurodegeneration (BPAN) caused by a novel WDR45 splice variant: a case study of an undiagnosed epileptic encephalopathy syndrome (ACMG 2026) - "Seizures are managed with brivaracetam, clobazam, and ketogenic diet. Metabolic testing was notable for normal acylcarnitine, free/total carnitine, plasma ammonia, and mildly elevated alanine. Notably, aspartate aminotransferase (AST) was also elevated."

Case study • Clinical • Ataxia • CNS Disorders • Developmental Disorders • Endocrine Disorders • Epilepsy • Genetic Disorders • Movement Disorders • Ophthalmology • Prader–Willi syndrome • Strabismus • ATP7A • FTL

Impact of Specialty Clinic Evaluation on Antiepileptic Prescribing Patterns in Patients with Angelman Syndrome (ACMG 2026) - "While there are no universally accepted guidelines for the pharmacologic management of epilepsy in Angelman syndrome, the literature increasingly recommends newer antiepileptic agents such as levetiracetam, lamotrigine, and clobazam as first-line agents in Angelman syndrome given their similar efficacy and more favorable side effect profile when compared to older antiepileptic medications such as valproate. This study demonstrates that engagement with the University of North Carolina Angelman Syndrome Clinic is associated with improved adherence to current recommendations for the pharmacologic management of epilepsy in Angelman syndrome. These findings highlight the value of multidisciplinary specialty clinic involvement in optimizing pharmacologic treatment plans and potentially improving overall clinical outcomes in patients with Angelman syndrome."

Clinical • CNS Disorders • Epilepsy

Bayesian-Based Pharmacokinetic Framework Integrated with Therapeutic Drug Monitoring for Assessing Adherence to Antiseizure Medications: A Clinical Trial Simulation Study. (PubMed, J Med Internet Res) - "This study proposed an innovative Bayesian-based pharmacokinetic (PK) framework integrated with TDM data to address the above limitations, with a focus on 14 widely prescribed ASMs, including brivaracetam, carbamazepine, clobazam, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, phenobarbital, topiramate, valproic acid, vigabatrin, and zonisamide. This study establishes a Bayesian-based PK approach to enhance the assessment of ASMs adherence. This approach facilitates a paradigm shift from population-based management to patient-specific adherence profiling, offering a practical methodology for the precise evaluation of medication-taking behaviors."

Journal • PK/PD data • CNS Disorders • Epilepsy

Medical Marijuana and Treatment Personalization: The Role of Genetics and Epigenetics in Response to THC and CBD. (PubMed, Genes (Basel)) - "The culmination is a proposal of tables and diagrams that organize the most important PGx-DDI-epigenetics relationships and facilitate the elimination of content repetition in the text. The paper identifies areas of implementation maturity (e.g., CYP2C9/THC, CBD-CYP2C19/clobazam, AKT1, and acute psychotomimetic effects) and those requiring replication (e.g., multigenic analgesic signals), indicating directions for future research."

Journal • Review • Pain • ABCB1 • AKT1 • COMT • CYP2C19 • CYP2C9 • CYP3A4 • UGT1A9

Efficacy and Safety of Clobazam Adjunctive Therapy in Pediatric Patients with Drug-Resistant Epilepsy. (PubMed, Drug Des Devel Ther) - "Adverse reactions occurred in 24 (24/146, 16.64%) patients, with excessive salivation/hypersalivation (4/146, 2.74%) and loss of appetite (4/146, 2.74%) being the most common. Clobazam adjunctive therapy is effective, safe and well tolerated in pediatric patients with drug-resistant epilepsy."

Journal • Retrospective data • Anorexia • CNS Disorders • Epilepsy • Pediatrics

Clobazam-Related Adverse Effects in Pediatric Patients Receiving Moderate to Strong CYP2C19 Inhibitors (ASHP 2025) - "Hosted by the Section of Clinical Specialists and Scientists"

Adverse events • Clinical • Pediatrics • CYP2C19

Navigating classical Hodgkin lymphoma in a patient with DIAPH1 deletion syndrome: Diagnostic and therapeutic challenges in a rare immuno-genetic context (ASH 2025) - P | "He was commenced on full dose OEPA (vincristine, etoposide, prednisolone, doxorubicin) after histopathologic confirmation of cHL, and following 2 cycles his early response assessment PET showed complete metabolic response. Due to concerns about hepatic enzyme induction and mitochondrial toxicity, anti-seizure therapy was changed to levetiracetam and clobazam, as carbamazepine is a potent CYP3A4 inducer that may decrease exposure to drugs like methylprednisolone (Bartoszek et al., 1987)...This is the first report showing feasibility of full dose induction therapy for cHL with intensive supportive care in DIAPH1 deficiency. Nonetheless, ongoing careful individualised dosing, vigilant toxicity monitoring, and multidisciplinary input remain essential."

Clinical • B Cell Lymphoma • Classical Hodgkin Lymphoma • CNS Disorders • Dental Disorders • Developmental Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mental Retardation • Mucositis • Neutropenia • Non-Hodgkin’s Lymphoma • Ophthalmology • Stomatitis • CYP3A4

Quality of life and synergistic combinations of antiseizure medication in patients treated with cenobamate in early therapy lines for focal-onset seizures. (PubMed, Epilepsy Behav) - "Our study provides evidence that CNB in early therapy lines for focal-onset seizures is associated with an increased HrQoL. Low-dose clobazam can wok synergistically with CNB. The combination with SV2A modulators showed a positive trend."

HEOR • Journal • CNS Disorders • Epilepsy

A Study of Adverse Drug Reactions to Antiepileptic Drugs in Pediatric Epileptic Patients From North India. (PubMed, Cureus) - "The study highlights that ADRs are more common in patients on conventional drugs like valproate, either as monotherapy or polytherapy. Use of newer drugs by physicians and reporting of ADRs by patients should be encouraged for the comprehensive management of childhood epilepsy."

Adverse drug reaction • Journal • CNS Disorders • Epilepsy • Pediatrics

Impact of clobazam on seizure control and antiseizure medication reduction in refractory brain tumor related epilepsy (SNO 2025) - "Despite failing other ASMs, the majority of patients who took clobazam became seizure free. While seizure freedom is the overall goal, reducing side effects is equally important for quality of life. After initiating clobazam, number and dosages of concurrent ASMs may also be reduced while maintaining seizure freedom or a reduced seizure frequency."

Brain Cancer • CNS Disorders • Epilepsy • Glioma • Oncology • Solid Tumor

Impact of clobazam on seizure control and antiseizure medication reduction in refractory brain tumor related epilepsy (SNO 2025) - "Despite failing other ASMs, the majority of patients who took clobazam became seizure free. While seizure freedom is the overall goal, reducing side effects is equally important for quality of life. After initiating clobazam, number and dosages of concurrent ASMs may also be reduced while maintaining seizure freedom or a reduced seizure frequency."

Brain Cancer • CNS Disorders • Epilepsy • Glioma • Oncology • Solid Tumor

Physiologically Based Pharmacokinetic Modeling of Clobazam and Stiripentol Co-Therapy in Dravet Syndrome. (PubMed, J Pers Med) - "Extrapolation to pediatric patients under two years of age predicted CLB, N-CLB, and STP exposures that were comparable to older children and remained within their reported efficacy and safety margins, suggesting no major ontogeny-related effect on exposure. The PBPK model supports the safe extrapolation of CLB and STP co-administration to pediatric Dravet syndrome patients as young as six months."

Journal • PK/PD data • CNS Disorders • Epilepsy • Pediatrics • CYP2C19

Stiripentol Use in Lennox-Gastaut Syndrome: Results from a Phase 2 Clinical Trial (AES 2025) - "They received an average of 3 ASMs, most commonly valproate (n=10) and clobazam (n=8). Despite the small sample size, stiripentol appeared to reduce seizure burden in LGS patients. These promising results support further investigation in a larger, controlled trial."

Clinical • Late-breaking abstract • P2 data • Absence Seizure Disorder • CNS Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder

Long-Term Use of Cannabidiol (Epidiolex) in Patients with Refractory Epilepsy - The UM Experience (AES 2025) - "The most frequently used prior ASM was clobazam (70%). Purified Pharmaceutical cannabidiol (CBD) provides modest seizure control in refractory epilepsy of multiple types. While adverse events were common, they led to discontinuation in only a quarter of patients. These real-world findings can provide valuable insights into its potential use in other epilepsy types beyond its current FDA-labeled indications."

Clinical • Late-breaking abstract • Anesthesia • CNS Disorders • Epilepsy • Psychiatry

Cenobamate in real world : a single center study (AES 2025) - "68 patients had a proactive decrease in one or several concomitant ASM dosage, mainly lacosamide (N=25), perampanel (N=14), clobazam (N=12). 51 patients needed a further decrease in other ASM dosage (mainly brivaracetam and lacosamide), and 52 patients could stop at least one concomitant ASM (mainly lacosamide and perampanel)... Efficacy of CNB is confirmed in this real world series of patients. After one year of follow up, the efficacy is maintained with 52% of the patients being either seizure free or responders. Side effects are common and in line with those found in regulatory studies."

Clinical • Real-world • Real-world evidence • Ataxia • CNS Disorders • Epilepsy • Movement Disorders

Corpus Callosotomy for Treatment of Infantile Epileptic Spasms Syndrome: The UCLA Experience (AES 2025) - "Median number of prior anti-seizure medications was 8 (IQR 7 – 10), and all subjects failed to respond to a trial of standard first-line therapy (prednisolone, ACTH, vigabatrin, or a combination thereof)...Patient 2 achieved seizure-freedom (now >1 yr) in response to cannabidiol and clobazam, prior to proposed surgical resection...After relapse with tonic seizures and epileptic spasms, both patients have since responded to cenobamate and remain seizure-free > 1yr... This study suggests that corpus callosotomy may aid in treatment of children with IESS, though the response rate in this series is lower than prior reports (Baba et al, 2018). Nevertheless, CC appears to be helpful in a substantial minority of patients, and CC should perhaps be considered much earlier in the course of epilepsy. Further study is clearly warranted to identify best candidates for CC in the setting of IESS."

CNS Disorders • Epilepsy

Longitudinal Patterns of Obstetrical and Neurological Care for Canadian Women with Epilepsy (1997-2023): Insights from the North American Anti-epileptic Drug Pregnancy Registry (NAAPR) (AES 2025) - "The top three anti-seizure medications at the time of last menstrual period were lamotrogine (25.1%), carbamazepine (23%), and levetiracetam (21.1%) with average reported total daily dose of 309.8 mg (SD = 165.8, range 50-1500), 761.5 mg (SD = 492,4, range 100-3600), and 1651.4 mg (SD = 1005.3, range 125-4000) respectively. Lesser used drugs were topiramate (6.8%), valproic acid (6.1%), and clobazam (0.9%) with an average total daily dose of 250.9 mg (SD = 136.8, range = 25-500), 855.8 mg (SD = 136.8, range = 25-500), and 42.5 mg (SD = 33.0, 10-80) respectively... This study provides one of the largest, multi-decade Canadian-specific data on PPWE to fill a critical gap in current research. Findings of this study can provide insight into important Canadian-specific differences compared to other population-based pregnancy registries."

Clinical • CNS Disorders • Epilepsy • Obstetrics